These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 30006734)

  • 1. Current trends in pharmacovigilance: value and gaps of patient reporting.
    Inácio P; Cavaco A; Airaksinen M
    Int J Clin Pharm; 2018 Aug; 40(4):754-757. PubMed ID: 30006734
    [No Abstract]   [Full Text] [Related]  

  • 2. Fifteen years of patient reporting -what have we learned and where are we heading to?
    van Hunsel F; Härmark L; Rolfes L
    Expert Opin Drug Saf; 2019 Jun; 18(6):477-484. PubMed ID: 31030578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Towards Drug Safety Surveillance and Pharmacovigilance: Current Progress in Detecting Medication and Adverse Drug Events from Electronic Health Records.
    Liu F; Jagannatha A; Yu H
    Drug Saf; 2019 Jan; 42(1):95-97. PubMed ID: 30649734
    [No Abstract]   [Full Text] [Related]  

  • 4. The value of patient reporting to the pharmacovigilance system: a systematic review.
    Inácio P; Cavaco A; Airaksinen M
    Br J Clin Pharmacol; 2017 Feb; 83(2):227-246. PubMed ID: 27558545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fifty years of pharmacovigilance - Medicines safety and public health.
    Laporte JR
    Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):725-32. PubMed ID: 26799344
    [No Abstract]   [Full Text] [Related]  

  • 6. Report of Adverse Events in Colombia: A Successful Case.
    Moreno-Mattar O; Ramírez R; Alvarado A; Sierra F; Guzmán J
    Curr Drug Saf; 2019; 14(1):53-56. PubMed ID: 30411692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Direct reporting by patients of adverse drug reactions in Spain].
    Esther Salgueiro M; Jimeno FJ; Aguirre C; García M; Ordóñez L; Manso G
    Farm Hosp; 2013; 37(1):65-71. PubMed ID: 23461502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Under-reporting of adverse drug reactions: a challenge for pharmacovigilance in India.
    Tandon VR; Mahajan V; Khajuria V; Gillani Z
    Indian J Pharmacol; 2015; 47(1):65-71. PubMed ID: 25821314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ongoing challenges in pharmacovigilance.
    Dal Pan GJ
    Drug Saf; 2014 Jan; 37(1):1-8. PubMed ID: 24264884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacovigilance implemented by patients: A necessity in the 21st century.
    Lafond J
    Therapie; 2016 Apr; 71(2):245-7. PubMed ID: 27080846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns in spontaneous adverse event reporting among branded and generic antiepileptic drugs.
    Bohn J; Kortepeter C; Muñoz M; Simms K; Montenegro S; Dal Pan G
    Clin Pharmacol Ther; 2015 May; 97(5):508-17. PubMed ID: 25670505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in the Netherlands: An explorative observational study.
    de Vries ST; Denig P; Ekhart C; Burgers JS; Kleefstra N; Mol PGM; van Puijenbroek EP
    Br J Clin Pharmacol; 2019 Jul; 85(7):1507-1515. PubMed ID: 30941789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse drug reactions in neonates: could we be documenting more?
    Hawcutt DB; O'Connor O; Turner MA
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):807-20. PubMed ID: 25225053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacovigilance workflow in Europe and Italy and pharmacovigilance terminology.
    Baldo P; Francescon S; Fornasier G
    Int J Clin Pharm; 2018 Aug; 40(4):748-753. PubMed ID: 30094557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value of case reports and spontaneous reporting systems for pharmacovigilance and clinical practice.
    Raschi E; La Placa M; Poluzzi E; De Ponti F
    Br J Dermatol; 2021 Mar; 184(3):581-583. PubMed ID: 33184850
    [No Abstract]   [Full Text] [Related]  

  • 17. Measuring the impact of pharmacovigilance activities, challenging but important.
    van Hunsel F; Gardarsdottir H; de Boer A; Kant A
    Br J Clin Pharmacol; 2019 Oct; 85(10):2235-2237. PubMed ID: 31368147
    [No Abstract]   [Full Text] [Related]  

  • 18. Surveillance of Drug Safety During Pregnancy: Insight in Current International Activities, Future Intentions and Need for Support of National Pharmacovigilance Centres.
    Kant A; de Vries L; Rolfes L
    Drug Saf; 2019 Jan; 42(1):35-43. PubMed ID: 30284215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [From pharmacovigilance to pharmacoepidemiology and risk coordination].
    Montastruc JL
    Rev Med Interne; 2009 Dec; 30 Suppl 4():S281-90. PubMed ID: 19892443
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacovigilance in Europe.
    Johnson CL; Hutchinson JA
    Transplantation; 2015 Aug; 99(8):1542-3. PubMed ID: 26308299
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.